Search
-
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Media
Decision on EU marketing authorisation expected for momelotinib by early 2024.
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/
First published: 13 November 2023
-
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Media
European Commission converts previous conditional approval to full approval as monotherapy for second-line dMMR/MSI-H endometrial cancer.
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-chemotherapy-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union/
First published: 11 December 2023
-
Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial
Media
Results reinforce development approach of using Jemperli as a backbone in immuno-oncology-based combination therapies
https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-zejula-combination-significantly-improved-progression-free-survival-in-endometrial-cancer-phase-iii-trial/
First published: 18 December 2023
-
European Commission authorises GSK’s Omjjara (momelotinib)
Media
First medicine in the EU specifically indicated for splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-omjjara-momelotinib/
First published: 29 January 2024
-
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Media
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-trial-continues-to-show-unprecedented-results/
First published: 03 June 2024
-
Jemperli (dostarlimab) plus chemotherapy application accepted for review by the European Medicines Agency to expand use to all patients with primary advanced or recurrent endometrial cancer
Media
Regulatory submission supported by statistically significant and clinically meaningful progression-free and overall survival data
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-plus-chemotherapy-application-accepted-for-review-by-ema/
First published: 24 June 2024
-
GSK profiles innovative R&D portfolio to investors
Media
40 potential new medicines and vaccines offer opportunity to drive long-term performance and deliver new benefits to patients and consumers
https://www.gsk.com/en-gb/media/press-releases/gsk-profiles-innovative-rd-portfolio-to-investors/
First published: 03 November 2015
-
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
Media
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) in patients with systemic lupus erythematosus
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-bliss-sc-study-of-benlysta-belimumab-administered-subcutaneously-in-patients-with-systemic-lupus-erythematosus/
First published: 07 November 2015
-
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Media
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
https://www.gsk.com/en-gb/media/press-releases/fda-grants-accelerated-approval-for-gsk-s-jemperli-dostarlimab-gxly-for-women-with-recurrent-or-advanced-dmmr-endometrial-cancer/
First published: 22 April 2021
-
Singapore
Locations
GSK Singapore
https://www.gsk.com/en-gb/locations/singapore/
First published: 27 June 2024